rs754320812
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PM1PM2PP3_StrongPP5_Very_Strong
The NM_001363118.2(SLC52A2):āc.935T>Cā(p.Leu312Pro) variant causes a missense change. The variant allele was found at a frequency of 0.0000859 in 1,606,368 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (ā ā ).
Frequency
Genomes: š 0.000046 ( 0 hom., cov: 33)
Exomes š: 0.000090 ( 0 hom. )
Consequence
SLC52A2
NM_001363118.2 missense
NM_001363118.2 missense
Scores
13
4
1
Clinical Significance
Conservation
PhyloP100: 6.19
Genes affected
SLC52A2 (HGNC:30224): (solute carrier family 52 member 2) This gene encodes a membrane protein which belongs to the riboflavin transporter family. In humans, riboflavin must be obtained by intestinal absorption because it cannot be synthesized by the body. The water-soluble vitamin riboflavin is processed to the coenzymes flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD) which then act as intermediaries in many cellular metabolic reactions. Paralogous members of the riboflavin transporter gene family are located on chromosomes 17 and 20. Unlike other members of this family, this gene has higher expression in brain tissue than small intestine. Alternative splicing of this gene results in multiple transcript variants encoding the same protein. Mutations in this gene have been associated with Brown-Vialetto-Van Laere syndrome 2 - an autosomal recessive progressive neurologic disorder characterized by deafness, bulbar dysfunction, and axial and limb hypotonia. [provided by RefSeq, Jul 2012]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 16 ACMG points.
PM1
In a hotspot region, there are 2 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 0 benign, 8 uncertain in NM_001363118.2
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.977
PP5
Variant 8-144360427-T-C is Pathogenic according to our data. Variant chr8-144360427-T-C is described in ClinVar as [Likely_pathogenic]. Clinvar id is 210041.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr8-144360427-T-C is described in UniProt as null. Variant chr8-144360427-T-C is described in UniProt as null. Variant chr8-144360427-T-C is described in UniProt as null. Variant chr8-144360427-T-C is described in UniProt as null. Variant chr8-144360427-T-C is described in UniProt as null. Variant chr8-144360427-T-C is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
SLC52A2 | NM_001363118.2 | c.935T>C | p.Leu312Pro | missense_variant | 3/5 | ENST00000643944.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
SLC52A2 | ENST00000643944.2 | c.935T>C | p.Leu312Pro | missense_variant | 3/5 | NM_001363118.2 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000460 AC: 7AN: 152284Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
7
AN:
152284
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000245 AC: 6AN: 245242Hom.: 0 AF XY: 0.0000300 AC XY: 4AN XY: 133536
GnomAD3 exomes
AF:
AC:
6
AN:
245242
Hom.:
AF XY:
AC XY:
4
AN XY:
133536
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000901 AC: 131AN: 1454084Hom.: 0 Cov.: 31 AF XY: 0.0000732 AC XY: 53AN XY: 723638
GnomAD4 exome
AF:
AC:
131
AN:
1454084
Hom.:
Cov.:
31
AF XY:
AC XY:
53
AN XY:
723638
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000460 AC: 7AN: 152284Hom.: 0 Cov.: 33 AF XY: 0.0000538 AC XY: 4AN XY: 74400
GnomAD4 genome
AF:
AC:
7
AN:
152284
Hom.:
Cov.:
33
AF XY:
AC XY:
4
AN XY:
74400
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ExAC
AF:
AC:
4
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:5Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Brown-Vialetto-van Laere syndrome 2 Pathogenic:2Other:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Nov 22, 2022 | Variant summary: GPR172A (SLC52A2) c.935T>C (p.Leu312Pro) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 2.5e-05 in 276638 control chromosomes (gnomAD). c.935T>C has been reported in the literature as a biallelic genotype in individuals affected with Brown-Vialetto Laere Syndrome (e.g. Foley_2014, Manole_2017, Marioli_2020). These data indicate that the variant is likely to be associated with disease. At least two publications report experimental evidence evaluating an impact on protein function (e.g. Foley_2014, Console_2022). The most pronounced variant effect results in approximately 40-50% of normal 3H-Riboflavin transport activity and displays a reduced binding affinity compared to the wildtype protein. Five submitters have provided clinical-significance assessments for this variant to ClinVar after 2014. All laboratories classified the variant as either pathogenic (n=2) or likely pathogenic (n=3). Based on the evidence outlined above, the variant was classified as likely pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Oct 08, 2023 | This sequence change replaces leucine, which is neutral and non-polar, with proline, which is neutral and non-polar, at codon 312 of the SLC52A2 protein (p.Leu312Pro). This variant is present in population databases (rs754320812, gnomAD 0.005%). This missense change has been observed in individuals with Brown-Vialetto-Van Laere syndrome (PMID: 24253200, 29053833). ClinVar contains an entry for this variant (Variation ID: 210041). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on SLC52A2 protein function. Experimental studies have shown that this missense change affects SLC52A2 function (PMID: 24253200). For these reasons, this variant has been classified as Pathogenic. - |
not provided, no classification provided | literature only | GeneReviews | - | - - |
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Center for Pediatric Genomic Medicine, Children's Mercy Hospital and Clinics | May 19, 2016 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Aug 19, 2024 | Observed with a pathogenic or likely pathogenic SLC52A2 variant in individuals with Brown-Vialetto-Van Laere syndrome, but it is not known whether the variants occurred on the same (in cis) or on different (in trans) chromosomes (PMID: 24253200, 29053833); Published functional studies demonstrate a damaging effect: reduced riboflavin uptake and reduced riboflavin transporter protein expression (PMID: 24253200); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 26633542, 34428344, 29053833, 24253200) - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 16, 2023 | The c.935T>C (p.L312P) alteration is located in exon 3 (coding exon 2) of the SLC52A2 gene. This alteration results from a T to C substitution at nucleotide position 935, causing the leucine (L) at amino acid position 312 to be replaced by a proline (P). Based on data from gnomAD, the C allele has an overall frequency of 0.003% (7/276638) total alleles studied. The highest observed frequency was 0.014% (1/7158) of Other alleles. This alteration has been reported in the homozygous state, and in conjunction with another alteration in SLC52A2, in multiple individuals with clinical features of Brown-Vialetto-Van Laere syndrome (Foley, 2014; Manole, 2017; Allison, 2017; Ambry internal data). This amino acid position is highly conserved in available vertebrate species. In vitro functional analysis of the p.L312P alteration showed a moderate decrease in 3H-transport activity compared with wild-type SLC52A2 (Foley, 2014). This alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, this alteration is classified as pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
DEOGEN2
Uncertain
D;D;.;D;D;D;D
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Pathogenic
D
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D;D;D;D;D;D;D
MetaSVM
Uncertain
D
MutationAssessor
Pathogenic
M;M;.;M;M;M;M
MutationTaster
Benign
D;D;D;D;D;D;D
PrimateAI
Pathogenic
D
PROVEAN
Pathogenic
D;D;D;D;D;D;.
REVEL
Pathogenic
Sift
Uncertain
D;D;D;D;D;D;.
Sift4G
Pathogenic
D;D;D;D;D;D;.
Polyphen
D;D;.;D;D;D;D
Vest4
MVP
MPC
0.69
ClinPred
D
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at